Pre-Clinical Pharmacological Profile of the Novel Glycoconjugate Org 36764 with both Factor Xa and Thrombin (IIa) Inhibitory Activities

Summary

Org 36764, is an antithrombin III (AT) and thrombin binding carbohydrate, which accelerates the inactivation of both factor Xa and thrombin by AT. It displays in buffer an anti-Xa and anti-thrombin activity of 415 and 2 U/mg, respectively, compared to 172 and 114 U/mg, respectively, for unfractionated heparin (UFH). Org 36764 does not cross-react with HIT (heparin induced thrombocytopenia) antibodies and is not neutralised by PF4. In experimental models in rats, on a molar basis, Org 36764 was more active than the pentasaccharide SanOrg 34006 (= AT binding domain of Org 36764) in arterial thrombosis, but both were equally active in venous thrombosis. In arterial thrombosis following endothelial damage by ferric chloride, Org 36764 was more active than the LMW heparin enoxaparin and SanOrg 34006 and similar active to UFH. At AT saturating doses the bleeding enhancement was not more than 3.5 times the control value. Org 36764 was more active in suppressing in vivo thrombus formation on stents than UFH, SanOrg 34006 or a combination of ticlopidine and aspirin. The results indicate that the novel drug Org 36764 is a drug with antithrombotic potential against venous and arterial thrombosis.

Keywords

Inhibitor - factor Xa/IIa - synthetic - antithrombotic

• References

• 1 Olson ST, Björk I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the anti-thrombin binding pentasaccharide in heparin Acceleration of antithrombin-proteinase reactions. J Biol Chem 1992; 267: 12528-38.
• 2 Olson ST, Björk I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost 1994; 20: 373-409.
• 3 Choay J, Lormeau JC, Petitou M, Sinay P, Fareed J. Structural studies on a biologically active hexasaccharide obtained from heparin. Ann NY Acad Sci 1981; 370: 644-9.
• 4 Grootenhuis PDJ, Westerduin P, Meuleman DG, Petitou M, van Boeckel CAA. Rational design of synthetic heparin analogues with tailor made coagulation factor inhibitory activity. Nature Structural Biol 1995; 02: 736-9.
• 5 Thunberg L, Bäckström G, Lindahl U. Further characterization of the antithrombin binding sequence in heparin. Carbohydr Res 1982; 100: 393-410.
• 6 Meuleman DG, Hobbelen PMJ, van Dinther TG, Vogel GMT, Van Boeckel CAA, Moelker HCT. Anti factor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: Discovery of compounds with a longer duration of action than of the natural pentasaccharide. Sem Thromb Hemost 1991; 17: 112-7.
• 7 Carrie D, Caranobe C, Salvib S, Houin G, Petitou M, Lormeau JC, Van Boeckel C, Meuleman D, Boneu B. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: Comparison with CY 216. Blood 1994; 84: 2571-7.
• 8 Westerduin P, van Boeckel CAA, Basten JEM, Broekhoven MA, Lucas H, Rood A, van der Heijden H, van Amsterdam RGM, van Dinther TG, Meuleman DG, Visser A, Vogel GMT, Damm JBL, Overklift GT. Feasible synthesis and biological properties of six ‘non-glycosamino’ glycan analogues of the antithrombin III binding heparin pentasaccharide. Bioorganic & Med Chem 1994; 02 (11) 1267-80.
• 9 Van Amsterdam RGM, Vogel GMT, Visser A, Kop WJ, Buiting MT, Meuleman DG. Synthetic analogues of the antithrombin III-binding pentasaccharide sequence of heparin Prediction of in vivo residence times. Arterioscler Thromb Vasc Biol 1995; 15: 495-503.
• 10 Herbert JM, Hérault JP, Bernat A, van Amsterdam RGM, Vogel GMT, Lormeau JC, Petitou M, Meuleman DG. Biochemical and pharmacological properties of SANORG32701V Comparison with the “Synthetic Pentasaccharide” (SR90107/Org31540) and standard heparin. Circ Res 1996; 79: 590-600.
• 11 Herbert JM, Hérault JP, Bernat A, van Amsterdam RGM, Lormeau JC, Petitou M, Hoffmann P, Meuleman DG. Biochemical and pharmacological properties of SANORG 34006 a potent and long-acting synthetic pentasaccharide. Blood 1998; 91: 4197-205.
• 12 Vogel GMT, Meuleman DG, Bourgondiën FGM, Hobbelen PMJ. Comparison of two experimental thrombosis models in rats Effects of four glycosaminoglycans. Thromb Res 1989; 54: 399-410.
• 13 Vogel GMT, van Amsterdam RGM, Zandberg P, van Houwelingen P, Kop WJ, van Mensvoort FWJ, Meuleman DG. Two new closely related rat models with relevance to arterial thrombosis Efficacies of different antithrombotic drugs. Thromb Haemost 1997; 01: 183-9.
• 14 De Scheerder I, Wang K, Wilczek K, Meuleman D, van Amsterdam R, Vogel G, Piessens J, van de Werf F. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997; 95: 1549-53.
• 15 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
• 16 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410.
• 17 Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67 (01) 27-30.
• 18 Meuleman DG, Vogel GMT, Van Delft AML. Effects of intra-arterial cannulation on blood platelet consumption in rats. Thromb Res 1980; 20: 45-55.
• 19 Marchalonis J. An enzymatic method for the trace iodination of immunoglobulins and other proteins. Biochem J 1969; 113: 299-305.
• 20 Bowman WC, Rand MJ. Textbook of pharmacology. Blackwell Scientific Publications. 1980. second edition. 41 37-41.43.
• 21 Westerduin P, van Basten JEM, Broekhoven MA, de Kimpe V, Kuijpers WHA, van Boeckel CAA. Synthese von maßgeschneiderten Glycokonjugaten, die AT-III vermittelt die Blutgerinnungsfaktoren Xa and Thrombin inhibieren. Angew Chem 1996; 108 (03) 330-42.
• 22 Van Amsterdam RGM, Vogel GMT, van As E, Groeneveld TM, Kop WJ, van Dinther TG, Meuleman DG. Novel glycoconjugate dual inhibitors of factor Xa and thrombin (IIa), fine-tuned to balance safety, efficacy and residence time. Haemostasis 1996; 26 (03) 176.
• 23 Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73: 235-40.
• 24 Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. In: Progress in Haemostasis and Thrombosis. 10. ed. by Coller B. S. 1991: 01-34.
• 25 Greinacher A, Michels I, Liebenhoff U, Presek P, Mueller-Eckhardt C. Heparin associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulfated oligosaccharide. Br J Haematol 1993; 84: 711-6.
• 26 Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-6.
• 27 Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterisation of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparinassociated thrombocytopenia. Thromb Haemost 1995; 74: 886-92.
• 28 Amiral J, Lormeau JC, Marfaing-Koka A, Vissac AM, Wolf M, BoyerNeumann C, Tardy B, Herbert JM, Meyer D. Absence of cross-reactivity of SR90107A/Org31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 08: 114-7.
• 29 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with lowmolecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20) 1330-5.
• 30 Serruys PW, Straus BH, Batt KJ, Bertrand ME, Puel J, Rickards AF, Meier B, Goy JJ, Vogt P, Kappenberg L, Sigwart U. Angiographic follow-up after placement of a self-expanding coronary artery stent. N Engl J Med 1991; 324: 13-7.
• 31 Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan H, Morel M-A. for the Benestent Study Group. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
• 32 Fishmann D, Leon M, Baim D, Schatz R, Savage M, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish D, Colombo A, Brinker J, Moses J, Shaknovich A, Hirsfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
• 33 Bucx JJJ, De Scheerder IK, Beatt K, van den Brand M, Suryapranata H, de Feyter PJ, Serruys PW. The importance of adequate anticoagulation to prevent early thrombosis after stenting of stenosed venous bypass grafts. Am Heart J 1991; 121: 1389-96.
• 34 De Scheerder IK, Strauss BH, de Feyter PJ, Beatt KJ, Bauer LHB, Wijns W, Heyndrix GR, Suryapranata H, van de Brand M, Buis B, Serruys PW, Morel MA, Montauban Evan Swijndrecht. Stenting of venous bypass grafts: a new treatment modality for patients who are poor candidates for reintervention. Am Heart J 1992; 123: 1046-54.
• 35 Rupprecht HJ, Darius H, Borkowski U, Voigtländer T, Nowak B, Genth S, Meyer J. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998; 97: 1046-52.
• 36 Bossavy JP, Thalamas C, Sagnard L, Barret A, Sakariassen K, Boneu B, Cadroy Y. A double-blind randomized comparison of combined aspirin and ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998; 92: 1518-25.
• 37 Vogel GMT, Van Amsterdam RGM, Kop WJ, Meuleman DG. Pentasaccharide and Orgaran® arrest, whereas heparin delays thrombus formation in a rat arterio-venous shunt. Thromb Haemost 1993; 69 (01) 29-34.